Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Breast Neoplasms 243Stomach Neoplasms 23Breast Neoplasms, Male 16Neoplasm Metastasis 14Neoplasms 8Inflammatory Breast Neoplasms 8Esophageal Neoplasms 8Brain Neoplasms 8Colorectal Neoplasms 6Adenocarcinoma Of Esophagus 4Urologic Neoplasms 3Triple Negative Breast Neoplasms 3HER2-positive Breast Cancer 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Ductal, Breast 3Gallbladder Neoplasms 2Endometrial Neoplasms 2Cholangiocarcinoma 2Carcinoma, Lobular 2Carcinoma, Intraductal, Noninfiltrating 2Biliary Tract Neoplasms 2Adenocarcinoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Solid Cancers 1Rectal Neoplasms 1Prostatic Neoplasms 1Patient Preference 1Patient Compliance 1

Interventions

pertuzumab 1atezolizumab 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × HER2-positive Metastatic Breast Cancer × Trastuzumab × Clear all
NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡